BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI) today announced the initiation of a pivotal, multi-center study of the Company’s lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body’s T cells to kill cancer cells.
